Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer
Édith Borcoman, Christophe Le Tourneau
Topics & Concepts
PembrolizumabMedicineOncologyDrug approvalCervical cancerCancerInternal medicineImmunotherapyPharmacologyDrugCancer Immunotherapy and BiomarkersBladder and Urothelial Cancer TreatmentsMultiple and Secondary Primary Cancers